Quantum dot-based HIV capture and imaging in a microfluidic channel

Kim, Yun‐Gon; Moon, Sangjun; Kuritzkes, Daniel R.; Demirci, Utkan

doi:10.1016/j.bios.2009.06.023

Cited by 109 publications

(91 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sample analysis based on the hybrid photonic-plasmonic approach is rapid since detection is potentially speed up through the use of optical forces that deliver proteins to the sites of high field intensity. With the challenges of surface functionalization, detection speed and microfluidic integration addressed, we propose that highly sensitive hybrid photonicplasmonic WGM biosensors in NP layers will have broad applications across multiple disciplines and areas including medical biosensing and drug screening [51,52]. …”

Section: Resultsmentioning

confidence: 99%

Ultrasensitive detection of a protein by optical trapping in a photonic‐plasmonic microcavity

Santiago-Cordoba

Çetinkaya

Boriskina

et al. 2012

Journal of Biophotonics

View full text Add to dashboard Cite

Microcavity and whispering gallery mode (WGM) biosensors derive their sensitivity from monitoring frequency shifts induced by protein binding at sites of highly confined field intensities, where field strengths can be further amplified by excitation of plasmon resonances in nanoparticle layers. Here, we propose a mechanism based on optical trapping of a protein at the site of plasmonic field enhancements for achieving ultra sensitive detection in only microliter-scale sample volumes, and in real-time. We demonstrate femto-Molar sensitivity corresponding to a few 1000 s of macromolecules. Simulations based on Mie theory agree well with the optical trapping concept at plasmonic hotspots locations. ((c) 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

show abstract

Section: Resultsmentioning

confidence: 99%

Ultrasensitive detection of a protein by optical trapping in a photonic‐plasmonic microcavity

Santiago-Cordoba

Çetinkaya

Boriskina

et al. 2012

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…The device was fabricated utilizing a laser cutter, as previously described. 4,7,14,30,31 The device had outer dimensions of 25 × 40 mm. PMMA and DSA layer thicknesses were 1.5 mm and 50 µm, respectively.…”

Section: Device Fabricationmentioning

confidence: 99%

“…11,12 In addition, reducing the concentration of cellular components of blood, and separating viruses in plasma using a rapid system may increase the capture efficiency microfluidic-based viral detection platforms. 13,14 This is particularly important for optical sensors, since the presence of blood cells in the sample can negatively affect the optical detection path and compromise accuracy. Detection technologies such as whispering gallerymode devices, 15 plasmon resonance devices, 16 and photonic crystals, 17 can benefit from the preremoval of nontargeted cells from whole blood to enhance the capture efficiency of targeted pathogens and proteins.…”

Section: Introductionmentioning

confidence: 99%

“…We separated viruses, which were 110-146 nm in size, 29 from whole blood using a microchip with 1-2 µm diameter porous filter membranes, which can be used as a preliminary on-chip step to detect viruses from whole blood by immunocapture. 13,14 We used HIV as a relevant virus model, and validated this microchip using hematological analysis and reverse transcription quantitative PCR (RT-qPCR). The presented work is the first demonstration of a simple, rapid, pump-free, antibody-free pathogen isolation device, which can reliably recover infectious agents using size-based separation from unprocessed whole blood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Simple filter microchip for rapid separation of plasma and viruses from whole blood

Wang¹,

Chen²,

Huang³

et al. 2012

IJN

Self Cite

View full text Add to dashboard Cite

Sample preparation is a significant challenge for detection and sensing technologies, since the presence of blood cells can interfere with the accuracy and reliability of virus detection at the nanoscale for point-of-care testing. To the best of our knowledge, there is not an existing on-chip virus isolation technology that does not use complex fluidic pumps. Here, we presented a lab-on-a-chip filter device to isolate plasma and viruses from unprocessed whole blood based on size exclusion without using a micropump. We demonstrated that viruses (eg, HIV) can be separated on a filter-based chip (2-µm pore size) from HIV-spiked whole blood at high recovery efficiencies of 89.9% ± 5.0%, 80.5% ± 4.3%, and 78.2% ± 3.8%, for viral loads of 1000, 10,000 and 100,000 copies/mL, respectively. Meanwhile, 81.7% ± 6.7% of red blood cells and 89.5% ± 2.4% of white blood cells were retained on 2 µm pore-sized filter microchips. We also tested these filter microchips with seven HIV-infected patient samples and observed recovery efficiencies ranging from 73.1% ± 8.3% to 82.5% ± 4.1%. These results are first steps towards developing disposable point-of-care diagnostics and monitoring devices for resource-constrained settings, as well as hospital and primary care settings.

show abstract

“…Microfluidics, with its inherent advantages of low sample and reagent volumes, multiplex and automated capabilities, and precise control over the microenvironment, has emerged as a promising operation platform with which to develop sensitive proteomic technologies. Several groups have used microfluidic sandwich immunoassays and enzymatic assays to demonstrate improvements in assay cost (1), amount of reagents and the starting sample needed (2, 3), assay times (4), and, most importantly, sensitivity (5)(6)(7)(8)(9)(10). However, to move away from "chips in labs" and to develop true "lab on a chip" technologies that can potentially be portable and even handheld, it is necessary to both miniaturize the fluidics and minimize the footprint of the instrumentation as a whole.…”

mentioning

confidence: 99%

Digital microfluidic assay for protein detection

Mok

Mindrinos

Davis

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

115

View full text Add to dashboard Cite

Global studies of the human proteome have revealed a plethora of putative protein biomarkers. However, their application for early disease detection remains at a standstill without suitable methods to realize their utility in the clinical setting. There thus continues to be tremendous interest in developing new technology for sensitive protein detection that is both low in cost and carries a small footprint to be able to be used at the point of care. The current gold standard method for protein biomarker detection is the ELISA, which measures protein abundance using bulky fluorescent scanners that lack portability. Here, we present a digital microfluidic platform for protein biomarker detection that is low in cost compared with standard optical detection methods, without any compromise in sensitivity. This platform furthermore makes use of simple electronics, enabling its translation into a portable handheld device, and has been developed in a manner that can easily be adapted to assay different types of proteomic biomarkers. We demonstrate its utility in quantifying not only protein abundance, but also activity. Interleukin-6 abundance could be assayed from concentrations as low as 50 pM (an order of magnitude lower than that detectable by a comparable laboratory designed ELISA) using less than 5 μL of sample, and Abelson tyrosine kinase activity was detectable in samples containing 100 pM of kinase.biosensor | decoupled architecture | bead-based assay R ecent decades of research have shown that the molecular mechanisms underlying human disease are much more complex than originally appreciated, with one or more rare genetic events often playing key roles in the transformation of a normal cell into a diseased cell. Not surprisingly, the diagnosis and treatment of many human diseases continue to struggle from the use of simplified models that are based on a handful of highly expressed biomarkers. Thanks to recent advances in microarray and next-generation sequencing technologies, a steadily increasing number of complete genomes have been sequenced, and considerable progress has been made using genomic biomarkers to better personalize healthcare. However, the ability to provide complete personalized healthcare demands the ability to monitor genetic biomarkers as well as protein biomarkers, and the development of proteomic technologies suitable for analyzing human samples has lagged considerably behind.To be well suited as a clinical diagnostic, a proteomic technology must be sensitive enough to detect endogenous levels of low abundance proteins, require low sample volumes, have a short assay time, and ideally be portable as to allow informed treatment decisions to be made at the point of care. Microfluidics, with its inherent advantages of low sample and reagent volumes, multiplex and automated capabilities, and precise control over the microenvironment, has emerged as a promising operation platform with which to develop sensitive proteomic technologies. Several groups have used microfluidic sandwich immunoassays ...

show abstract

Quantum dot-based HIV capture and imaging in a microfluidic channel

Cited by 109 publications

References 30 publications

Ultrasensitive detection of a protein by optical trapping in a photonic‐plasmonic microcavity

Ultrasensitive detection of a protein by optical trapping in a photonic‐plasmonic microcavity

Simple filter microchip for rapid separation of plasma and viruses from whole blood

Digital microfluidic assay for protein detection

Contact Info

Product

Resources

About